FULLTEST
TEST BANK FOR PHARMACOTHERAPEUTICS FOR
a
a
a a
a
a
ADVANCED PRACTICE A PRACTICAL APPROACH 5TH a a a a a
EDITION BY VIRGINIA POOLE ARCANGELO; ANDREW
a a a a a a
PETERSON; VERONICA WILBUR; JENNIFER A. REINHOLD
a a a a a a
PRINTED PDF I ORIGINAL DIRECTLY FROM THE PUBLISHER I 1OO%
a a a a a a a a a
VERIFIED ANSWERS ] DOWNLOAD IMMEDIATELY AFTER THE ORDER
a a a a a a a a
['LIZ)LI12%5IL!
[LI.GIL
Complete Test bank, All Chapters are included.
a a a a a a
For more Test banks, ATI, HES! exams, and more contact us.
a a a a a a a a a a
, Tableofcontent a a
Chapter I Issues for the Practitioner in Drug Therapy
a a a a a a a a
Chapter 2 Pharmacokinetic Basis ofTherapeutics and Pharmacodynamic Principles
a a a a a a a a
Chapter 3 Impact of Drug Interactions and Adverse Events on Therapeutics Chapter 4
a a a a a a a a a a a a a
Principles of Pharmacotherapy in Pediatrics, Pregnancy, and Lactation Chapter 5
a a a a a a a a a a
Pharmacotherapy Principles in Older Adults
a a a a a
Chapter 6 Principles ofAntimicrobial Therapy Chapter
a a a a a a
7 Pharmacogenomies
a a
Chapter 8 The Economics ofPharmacotherapeutics
a a a a a
Chapter 9 Pharmacotherapy of Pain Management
a a a a a a
Chapter I0 Pain Management in Opioid Use Disorder (OUD) Patients
a a a a a a a a a
Chapter 11 Cannabis and Pain Management
a a a a a a
Chapter 12 Contact Dermatitis
a a a
Chapter 13 Fungal, Viral, and Bacterial Infections ofthe Skin
a a a a a a a a a
Chapter 14 Psoriasis
a a a
Chapter I5 Acne Vulgaris and Rosacea Chapter
a a a a a a
16 Ophthalmic Disorders
a a a
Chapter I7 Otitis Media and Otitis Externa
a a a a a a
Chapter I8 Hypertension
a a a
Chapter I9 Hyperlipidemia
a a
Chapter 20 Chronic Stable Angina and Myocardial Infarction
a a a a a a a
Chapter 2I Heart Failure
a a a a
Chapter 22 Arrhythmias
a a
Chapter 23 Respiratory Infections
a a a
Chapter 24 Asthma and Chronic Obstructive Pulmonary Disease Chapter
a a a a a a a a
25 Gastric, Functional, and Inflammatory Bowel Disorders Chapter 26
a a a a a a a a a
Gastroesophageal Reflux Disease and Peptic Ulcer Disease Chapter 27
a a a a a a a a a
Liver Diseases
a a
Chapter 28 Urinary Tract Infection
a a a a
Chapter 29 Prostatic Disorders and Erectile Dysfunction Chapter
a a a a a a a
30 Overactive Bladder
a a a
Chapter 3I Sexually Transmitted Infections
a a a a
Chapter 32 Osteoarthritis and Gout
a a a a a
aChapter 33 Osteoporosisa a
Chapter 34 Rheumatoid Arthritis
a a a
Chapter 35 Headaches
a a a
Chapter 36 Seizure Disorders
a a a
Chapter37 Alzheimer's Disease
a a a a
Chapter 38 Parkinson's Disease
a a a a
Chapter 39 Major Depressive Disorder and Bipolar Disorders
a a a a a a a
Chapter 40 Anxiety Disorders
a a a a
Chapter41 Sleep Disorders
a a a
Chapter 42 Attention Deficit Hyperactivity Disorder
a a a a a
Chapter 43 Substance Use Disorders
a a a a a
Chapter 44 Diabetes Mellitus
a a a
Chapter 45 Thyroid and Parathyroid Disorders
a a a a a
,Chapter 46 Allergies and Allergic Reactions
a a a a a
Chapter47 HumanImmunodeficiencyVirus
a a a a a
Chapter 48 Organ Transplantation
a a a a
Chapter 49 Thromboembolic Disorders
a a a
Chapter 50 Anemias
a a a
Chapter 5l Immunizations
a a
Chapter52Smoking Cessation
a a a a
Chapter 53 Weight Loss Chapter
a a a a a
54 Contraception
a a
Chapter 55 Menopause
a a
Chapter 56 Vaginitis
a a
, lOMoAR a cPSD|
a21007614
lOMoAR a cPSD| a 21007614
Chapter 1 Issues for the Practitioner in Drug Therapy
a a a a a a a a
MULTIPLE CHOICE a
1. Nurse practitioner prescriptive authority is regulated by:
a a a a a a
A. The National Council of State Boards of Nursing
a a a a a a a
B. The U.S. Drug Enforcement Administration
a a a a
C. The State Board of Nursing for each state
a a a a a a a
D. The State Board of Pharmacy
a a a a
ANS: C a PTS: 1 a
2. Physician Assistant (PA) prescriptive authority is regulated by:
a a a a a a a
A. The National Council of State Boards of Nursing
a a a a a a a
B. The U.S. Drug Enforcement Administration
a a a a
C. The State Board of Nursing
a a a a
D. The State Board of Medical Examiners
a a a a a
ANS: D a PTS: 1 a
3. Clinical judgment in prescribing includes:
a a a a
A. Factoring in the cost to the patient of the medication prescribed
a a a a a a a a a a
B. Always prescribing the newest medication available for the disease process
a a a a a a a a a
C. Handing out drug samples to poor patients a a a a a a
D. Prescribing all generic medications to cut costs a a a a a a
ANS: A a PTS: 1 a
4. Criteria for choosing an effective drug for a disorder include:
a a a a a a a a a
A. Asking the patient what drug they think would work best for them
a a a a a a a a a a a
B. Consulting nationally recognized guidelines for disease management a a a a a a
C. Prescribing medications that are available as samples before writing a prescription
a a a a a a a a a a
D. Following U.S. Drug Enforcement Administration (DEA) guidelines for
a a a a a a a
a prescribing
ANS: B a PTS: 1 a
5. Nurse practitioner practice may thrive under health-care reform due to:
a a a a a a a a a
A. The demonstrated ability of nurse practitioners to control costs and improve patient
a a a a a a a a a a a
a outcomes
B. The fact that nurse practitioners will be able to practice independently
a a a a a a a a a a
C. The fact that nurse practitioners will have full reimbursement under health-care
a a a a a a a a a a
reform
a
D. The ability to shift accountability for Medicaid to the state level
a a a a a a a a a a
ANS: A a PTS: 1 a
TEST BANK FOR PHARMACOTHERAPEUTICS FOR
a
a
a a
a
a
ADVANCED PRACTICE A PRACTICAL APPROACH 5TH a a a a a
EDITION BY VIRGINIA POOLE ARCANGELO; ANDREW
a a a a a a
PETERSON; VERONICA WILBUR; JENNIFER A. REINHOLD
a a a a a a
PRINTED PDF I ORIGINAL DIRECTLY FROM THE PUBLISHER I 1OO%
a a a a a a a a a
VERIFIED ANSWERS ] DOWNLOAD IMMEDIATELY AFTER THE ORDER
a a a a a a a a
['LIZ)LI12%5IL!
[LI.GIL
Complete Test bank, All Chapters are included.
a a a a a a
For more Test banks, ATI, HES! exams, and more contact us.
a a a a a a a a a a
, Tableofcontent a a
Chapter I Issues for the Practitioner in Drug Therapy
a a a a a a a a
Chapter 2 Pharmacokinetic Basis ofTherapeutics and Pharmacodynamic Principles
a a a a a a a a
Chapter 3 Impact of Drug Interactions and Adverse Events on Therapeutics Chapter 4
a a a a a a a a a a a a a
Principles of Pharmacotherapy in Pediatrics, Pregnancy, and Lactation Chapter 5
a a a a a a a a a a
Pharmacotherapy Principles in Older Adults
a a a a a
Chapter 6 Principles ofAntimicrobial Therapy Chapter
a a a a a a
7 Pharmacogenomies
a a
Chapter 8 The Economics ofPharmacotherapeutics
a a a a a
Chapter 9 Pharmacotherapy of Pain Management
a a a a a a
Chapter I0 Pain Management in Opioid Use Disorder (OUD) Patients
a a a a a a a a a
Chapter 11 Cannabis and Pain Management
a a a a a a
Chapter 12 Contact Dermatitis
a a a
Chapter 13 Fungal, Viral, and Bacterial Infections ofthe Skin
a a a a a a a a a
Chapter 14 Psoriasis
a a a
Chapter I5 Acne Vulgaris and Rosacea Chapter
a a a a a a
16 Ophthalmic Disorders
a a a
Chapter I7 Otitis Media and Otitis Externa
a a a a a a
Chapter I8 Hypertension
a a a
Chapter I9 Hyperlipidemia
a a
Chapter 20 Chronic Stable Angina and Myocardial Infarction
a a a a a a a
Chapter 2I Heart Failure
a a a a
Chapter 22 Arrhythmias
a a
Chapter 23 Respiratory Infections
a a a
Chapter 24 Asthma and Chronic Obstructive Pulmonary Disease Chapter
a a a a a a a a
25 Gastric, Functional, and Inflammatory Bowel Disorders Chapter 26
a a a a a a a a a
Gastroesophageal Reflux Disease and Peptic Ulcer Disease Chapter 27
a a a a a a a a a
Liver Diseases
a a
Chapter 28 Urinary Tract Infection
a a a a
Chapter 29 Prostatic Disorders and Erectile Dysfunction Chapter
a a a a a a a
30 Overactive Bladder
a a a
Chapter 3I Sexually Transmitted Infections
a a a a
Chapter 32 Osteoarthritis and Gout
a a a a a
aChapter 33 Osteoporosisa a
Chapter 34 Rheumatoid Arthritis
a a a
Chapter 35 Headaches
a a a
Chapter 36 Seizure Disorders
a a a
Chapter37 Alzheimer's Disease
a a a a
Chapter 38 Parkinson's Disease
a a a a
Chapter 39 Major Depressive Disorder and Bipolar Disorders
a a a a a a a
Chapter 40 Anxiety Disorders
a a a a
Chapter41 Sleep Disorders
a a a
Chapter 42 Attention Deficit Hyperactivity Disorder
a a a a a
Chapter 43 Substance Use Disorders
a a a a a
Chapter 44 Diabetes Mellitus
a a a
Chapter 45 Thyroid and Parathyroid Disorders
a a a a a
,Chapter 46 Allergies and Allergic Reactions
a a a a a
Chapter47 HumanImmunodeficiencyVirus
a a a a a
Chapter 48 Organ Transplantation
a a a a
Chapter 49 Thromboembolic Disorders
a a a
Chapter 50 Anemias
a a a
Chapter 5l Immunizations
a a
Chapter52Smoking Cessation
a a a a
Chapter 53 Weight Loss Chapter
a a a a a
54 Contraception
a a
Chapter 55 Menopause
a a
Chapter 56 Vaginitis
a a
, lOMoAR a cPSD|
a21007614
lOMoAR a cPSD| a 21007614
Chapter 1 Issues for the Practitioner in Drug Therapy
a a a a a a a a
MULTIPLE CHOICE a
1. Nurse practitioner prescriptive authority is regulated by:
a a a a a a
A. The National Council of State Boards of Nursing
a a a a a a a
B. The U.S. Drug Enforcement Administration
a a a a
C. The State Board of Nursing for each state
a a a a a a a
D. The State Board of Pharmacy
a a a a
ANS: C a PTS: 1 a
2. Physician Assistant (PA) prescriptive authority is regulated by:
a a a a a a a
A. The National Council of State Boards of Nursing
a a a a a a a
B. The U.S. Drug Enforcement Administration
a a a a
C. The State Board of Nursing
a a a a
D. The State Board of Medical Examiners
a a a a a
ANS: D a PTS: 1 a
3. Clinical judgment in prescribing includes:
a a a a
A. Factoring in the cost to the patient of the medication prescribed
a a a a a a a a a a
B. Always prescribing the newest medication available for the disease process
a a a a a a a a a
C. Handing out drug samples to poor patients a a a a a a
D. Prescribing all generic medications to cut costs a a a a a a
ANS: A a PTS: 1 a
4. Criteria for choosing an effective drug for a disorder include:
a a a a a a a a a
A. Asking the patient what drug they think would work best for them
a a a a a a a a a a a
B. Consulting nationally recognized guidelines for disease management a a a a a a
C. Prescribing medications that are available as samples before writing a prescription
a a a a a a a a a a
D. Following U.S. Drug Enforcement Administration (DEA) guidelines for
a a a a a a a
a prescribing
ANS: B a PTS: 1 a
5. Nurse practitioner practice may thrive under health-care reform due to:
a a a a a a a a a
A. The demonstrated ability of nurse practitioners to control costs and improve patient
a a a a a a a a a a a
a outcomes
B. The fact that nurse practitioners will be able to practice independently
a a a a a a a a a a
C. The fact that nurse practitioners will have full reimbursement under health-care
a a a a a a a a a a
reform
a
D. The ability to shift accountability for Medicaid to the state level
a a a a a a a a a a
ANS: A a PTS: 1 a
